Disclosure of interest: Lino Braadt: nothing to disclose, Markus Naumann: nothing to disclose, Dennis Freuer: nothing to disclose, Christa Meisinger: nothing to disclose, Jakob Linseisen: nothing to disclose, Michael Ertl: nothing to disclose Scientific Communications: atherosclerosis and stroke 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.04 - STROKE COMPLICATIONS O - ESOC25-536 SAFETY AND EFFICACY OF DRUG-COATED BALLOON IN PATIENTS WITH SEVERE VERTEBRAL ARTERY ORIGIN STENOSIS (DCB-VAOS): A MULTICENTRE RANDOMISED TRIAL Liqun Jiao 1 , Yabing Wang 1 , Tao Wang 1,1 , Jichang Luo 1 , Rixuan Peng 1 , Changchun Jiang 2 , Haibo Wang 3 1 The Departments of Neurosurgery and Interventional Neuroradiology, Beijing, China, 2 Department of Neurology, Inner Mongolia Autonomous Region, China, 3 Peking University Clinical Research Institute, Beijing, China Background and Aims: Restenosis post endovascular treatment of vertebral artery origin stenosis (VAOS), with/without a bare-metal stent (BMS) and linked to recurrent stroke/death, is high compared to other vascular lesions
Microinfusion is the most reliable consumer-accessible method for crossing the stratum corneum at therapeutic delivery levels
it's valuable information about your biochemistry
What is the difference between GHK-Cu and Copper Tripeptide-1
